Scientists test 'Gene Silencing' shot to fight advanced cancers
NCT ID NCT01591356
Summary
This is an early safety study testing a new type of intravenous drug called EphA2 siRNA in patients with advanced solid tumors that have spread or returned after treatment. The drug is designed to slow cancer growth by 'silencing' a specific gene that helps tumors grow. The main goals are to find the safest dose and understand the side effects in up to 49 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.